Home » Topics » BioWorld Science

BioWorld Science
RSS

Thalidomide in phase II at NCI for cancer indications

April 12, 1996

Banyu reports synthesis and activity of BE-39907A2

April 12, 1996

Banyu discovers new thioredoxin system inhibitor

April 12, 1996

Isis, Ciba-Geigy evaluate antisense drug in phase I

April 12, 1996

BR96 produced successfully in milk from transgenic goats

April 12, 1996

Virulizin clinical trials resume in pancreatic cancer

April 12, 1996

Gastrimmune phase I/II trial completed

April 12, 1996

Corixa in-licenses Optivax delivery system for vaccines

April 12, 1996

Amiprilose advances to phase III in rheumatoid arthritis

April 12, 1996

COX-2 inhibitor research continues at Merck Frosst

April 12, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...